Rein Therapeutics Inc. (NASDAQ:RNTX) Receives Consensus Rating of “Hold” from Brokerages

Rein Therapeutics Inc. (NASDAQ:RNTX) has earned a consensus rating of “Hold” from the four analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $6.00.

Several research analysts have recently weighed in on RNTX shares. Maxim Group began coverage on Rein Therapeutics in a research note on Monday, July 20th. They set a “buy” rating and a $4.00 target price for the company. Wall Street Zen raised shares of Rein Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. HC Wainwright dropped their price target on Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Finally, Weiss Ratings cut Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of RNTX. Voss Capital LP raised its stake in shares of Rein Therapeutics by 59.2% during the fourth quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock valued at $4,923,000 after purchasing an additional 1,577,437 shares during the period. Vanguard Group Inc. boosted its stake in Rein Therapeutics by 32.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock valued at $1,338,000 after acquiring an additional 284,300 shares during the last quarter. Cable Car Capital LP acquired a new position in Rein Therapeutics during the 2nd quarter worth $588,000. Sigma Planning Corp grew its holdings in Rein Therapeutics by 41.0% during the 1st quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock worth $453,000 after acquiring an additional 101,400 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Rein Therapeutics by 15.1% in the fourth quarter. Geode Capital Management LLC now owns 284,555 shares of the company’s stock worth $330,000 after purchasing an additional 37,244 shares in the last quarter. Institutional investors and hedge funds own 90.89% of the company’s stock.

Rein Therapeutics Price Performance

NASDAQ:RNTX opened at $0.79 on Monday. The stock’s 50 day simple moving average is $0.97 and its two-hundred day simple moving average is $1.19. Rein Therapeutics has a 1 year low of $0.76 and a 1 year high of $2.18. The company has a market cap of $67.69 million, a price-to-earnings ratio of -0.42 and a beta of 1.35.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.30. As a group, analysts anticipate that Rein Therapeutics will post -0.53 EPS for the current year.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.